Subscribe to RSS

DOI: 10.1055/a-1784-0166
Yield of upper gastrointestinal screening in colonic adenomatous polyposis of unknown etiology: a multicenter study

Abstract
Background and study aims The majority of patients with 10 or more cumulative colorectal adenomas have uninformative genetic testing and meet criteria for colonic adenomatous polyposis of unknown etiology (CPUE). The yield of upper gastrointestinal screening in patients with CPUE after multi-gene panel testing is unknown and our objective was to characterize this.
Patient and methods A multicenter, retrospective analysis of screening upper endoscopies in adults with CPUE after multi-gene panel testing was performed. Those with a history of gastroduodenal neoplasia prior to CPUE diagnosis were excluded. Demographic and clinical variables were collected and compared.
Results One hundred and twenty-eight patients with CPUE were included from five participating centers. Nine (7.0 %) had gastroduodenal neoplasia on initial screening upper endoscopy. Those with over 100 colorectal adenomas had a significantly higher rate of gastroduodenal neoplasia than those with 20–99 or 10–19 colorectal adenomas (44.4 % vs 4.1 % vs 4.4 %, P = 0.002). Similar results were seen when the analysis was restricted to only duodenal or ampullary adenomas. The only malignancy was a gastric cancer in a patient with 20 to 99 colorectal adenomas. When comparing patients with gastroduodenal neoplasia to those without, the only significantly different characteristic was the cumulative number of colorectal adenomas.
Conclusions We found a 7 % rate of gastroduodenal neoplasia in patients with CPUE after multi-gene panel testing. Although patients with ≥ 100 colorectal adenomas had a significantly higher risk, over 4 % of patients with 10 to 99 colorectal adenomas had gastroduodenal neoplasia. Given this, we recommend a screening upper endoscopy at the time of a colonoscopy after CPUE diagnosis.
Publication History
Received: 12 August 2021
Accepted after revision: 24 November 2021
Article published online:
14 April 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Tieu AH, Edelstein D, Axilbund J. et al. Clinical characteristics of multiple colorectal adenoma patients without germline APC or MYH mutations. J Clin Gastroenterol 2016; 50: 584-588
- 2 Kallenberg FGJ, Latchford A, Lips NC. et al. Duodenal adenomas in patients with multiple colorectal adenomas without germline APC or MUTYH Mutations. Dis Colon Rectum 2018; 61: 58-66
- 3 National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal. In, NCCN Clinical Practice Guidelines in Oncology; Version 1.2020.
- 4 Monahan KJ, Bradshaw N, Dolwani S. et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut 2020; 69: 411-444
- 5 Syngal S, Brand RE, Church JM. et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110: 223-262; quiz 263
- 6 Valle L, de Voer RM, Goldberg Y. et al. Update on genetic predisposition to colorectal cancer and polyposis. Mol Aspects Med 2019; 69: 10-26
- 7 Stanich PP, Pearlman R, Hinton A. et al. Prevalence of germline mutations in polyposis and colorectal cancer-associated genes in patients with multiple colorectal polyps. Clin Gastroenterol Hepatol 2019; 17: 2008-2015.e3
- 8 Heald B, Hampel H, Church J. et al. Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis. Fam Cancer 2020; 19: 223-239
- 9 Rosty C, Brosens LAA, Dekker E. et al. WHO Classification of Tumours: Digestive System Tumours. Lyon, France: International Agency for Research on Cancer; 2019: 532-534
- 10 Yurgelun MB, Hornick JL, Curry VK. et al. Therapy-associated polyposis as a late sequela of cancer treatment. Clin Gastroenterol Hepatol 2014; 12: 1046-1050
- 11 Harris PA, Taylor R, Thielke R. et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-381
- 12 Harris PA, Taylor R, Minor BL. et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019; 95: 103208
- 13 Culver EL, McIntyre AS. Sporadic duodenal polyps: classification, investigation, and management. Endoscopy 2011; 43: 144-155
- 14 Bulow S, Bjork J, Christensen IJ. et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004; 53: 381-386
- 15 Thomas LE, Hurley JJ. Collaborative Group on Duodenal Polyposis in MAP. et al. Duodenal adenomas and cancer in MUTYH-associated polyposis: an international cohort study. Gastroenterology 2021; 160: 952-954.e4